Tigermed EMEA – Achievements, Expertise, and Major Contributions in Clinical Research

Tigermed EMEA represents the European, Middle East, and Africa division of the global Tigermed Group – a full-service CRO with international coverage, supporting the development of pharmaceuticals and medical devices across all phases of clinical research. With rapid expansion throughout the EMEA region and a growing project portfolio, the company has strengthened its position as a strategic partner for sponsors aiming to accelerate therapy development and achieve efficient market access.

1. Tigermed EMEA’s Footprint in the EMEA Region

According to public company data, Tigermed EMEA has a strong and well-structured presence:

• operations in over 20 EMEA countries,

• 15 local offices,

• a team of 160+ specialists across Europe,

• experience in over 200 Phase I–IV clinical studies conducted in the region.

At the group level, Tigermed considers EMEA a strategic pillar, with over 100 multi-regional clinical trials (MRCT)conducted in Europe and involvement in more than 210 clinical projects by 2025.

2. Major Achievements and Strategic Contributions in Clinical Research

1-Over 200 Clinical Studies in EMEA (Phase I–IV)

The Tigermed EMEA portfolio includes studies across various therapeutic areas: oncology, endocrinology/metabolic diseases, neurology (CNS), infectious diseases, cardiovascular, rheumatology, and ophthalmology — including complex multi-country projects.

2- Proven Expertise in Large-Scale Vaccine Studies

Tigermed EMEA has demonstrated experience in managing large-scale vaccine trials, supported by Tigermed’s global infrastructure.

At the group level, Tigermed has contributed to COVID-19 vaccine programs by conducting accelerated multi-regional studies, directly supporting rapid approval pathways.

3- Participation in the Approval of Innovative Drugs and Medical Devices

Global Tigermed reports highlight:

• 567 drug studies and

• 341 medical device projects conducted in a single year,

as well as direct contributions to the approval of:

• three innovative medical devices,

• two AI-based medical software solutions,

• and support in achieving market approval for a new CGRP receptor antagonist for migraine, in collaboration with a global sponsor.

Tigermed EMEA played a key role in the European components of these programs, contributing operational, regulatory, and pharmacovigilance expertise.

4- Leadership in Decentralized Clinical Trials and Digitalization (DCT)

Tigermed is a pioneer in DCT, implementing:

• hybrid studies with ePRO,

• telemedicine,

• digital tools for remote data collection,

• home IMP delivery,

• and fully digital study management.

Notably, Tigermed implemented a DCT component for the Nurtec® migraine study, enabling digital data collection.

Tigermed EMEA integrates these practices across Europe, adapting them to CTR and local regulatory requirements.

5- Expanding Clinical Research Across Africa

Tigermed and Tigermed EMEA collaborate with organizations such as Purpose Africa and Africare to:

• expand clinical site networks,

• increase patient access to trials,

• develop local research infrastructure,

• and support multi-regional studies across African regions.

This initiative helps sponsors include diverse patient populations and access emerging markets.

3. Types of Clinical Studies Successfully Conducted

Tigermed EMEA has extensive experience in:

Drug Studies (Phase I–IV)

• oncology (including cell and gene therapies),

• metabolic diseases,

• infectious diseases,

• cardiovascular diseases,

• neurological and rheumatological disorders.

Vaccine Studies

• traditional vaccines (influenza, HPV, etc.),

• innovative vaccine platforms, including COVID-19.

Medical Device and IVD Studies

• implantable and non-implantable devices,

• medical software and AI-based solutions,

• performance and safety studies under MDR/IVDR.

Cosmetics, Nutraceuticals, and Supplements

• efficacy evaluations,

• post-marketing observational studies.

Multi-Regional Clinical Trials (MRCT)

Including:

• feasibility,

• site selection,

• project management,

• data management & statistical analysis,

• regulatory support (CTR, MDR, IVDR),

• and integrated pharmacovigilance.

4. Why Sponsors Choose Tigermed EMEA

Tigermed EMEA’s results translate into clear advantages for partners:

• Reduced risk and accelerated approval timelines, supported by proven experience in hundreds of studies.

• An extensive network of clinical sites across 20+ countries, ideal for MRCT.

• Strong expertise in large vaccine studies, medical devices, and AI-enabled solutions, rapidly growing segments.

• A unique ability to combine global capabilities with local expertise across EMEA.

• Implementation of modern technologies (DCT, ePRO, telemedicine) for superior operational efficiency.